Progressive hemifacial atrophy: a review
Open Access
- 1 April 2015
- journal article
- review article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 10 (1) , 1-13
Abstract
Progressive Hemifacial Atrophy (PHA) is an acquired, typically unilateral, facial distortion with unknown etiology. The true incidence of this disorder has not been reported, but it is often regarded as a subtype of localized scleroderma. Historically, a debate existed whether PHA is a form of linear scleroderma, called morphea en coup de sabre (ECDS), or whether these conditions are inherently different processes or appear on a spectrum (; Adv Exp Med Biol 455:101–4, 1999; J Eur Acad Dermatol Venereol 19:403–4, 2005). Currently, it is generally accepted that both diseases exist on a spectrum of localized scleroderma and often coexist. The pathogenesis of PHA has not been delineated, but trauma, autoimmunity, infection, and autonomic dysregulation have all been suggested. The majority of patients have initial manifestations in the first two decades of life; however, late presentations in 6th and 7th decades are also described [J Am Acad Dermatol 56:257–63, 2007; J Postgrad Med 51:135–6, 2005; Neurology 61:674–6, 2003]. The typical course of PHA is slow progression over 2-20 years and eventually reaching quiescence. Systemic associations of PHA are protean, but neurological manifestations of seizures and headaches are common [J Am Acad Dermatol 56:257–63, 2007; Neurology 48:1013–8, 1997; Semin Arthritis Rheum 43:335–47, 2013]. As in many rare diseases, standard guidelines for imaging, treatment, and follow-up are not defined. This review is based on a literature search using PubMed including original articles, reviews, cases and clinical guidelines. The search terms were “idiopathic hemifacial atrophy”, “Parry-Romberg syndrome”, “Romberg’s syndrome”, “progressive hemifacial atrophy”, “progressive facial hemiatrophy”, “juvenile localized scleroderma”, “linear scleroderma”, and “morphea en coup de sabre”. The goal of this review is to summarize clinical findings, theories of pathogenesis, diagnosis, clinical course, and proposed treatments of progressive hemifacial atrophy using a detailed review of literature. Review articles were used to identify primary papers of interest while retrospective cohort studies, case series, case reports, and treatment analyses in the English language literature or available translations of international literature were included.Keywords
This publication has 153 references indexed in Scilit:
- Updates on Morphea: Role of Vascular Injury and Advances in TreatmentAutoimmune Diseases, 2013
- Parry-Romberg Syndrome Presenting as Status MigrainosusPediatric Neurology, 2009
- A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized sclerodermaJournal of the American Academy of Dermatology, 2006
- Clinical and serological characteristics of progressive facial hemiatrophy: A case series of 12 patientsJournal of the American Academy of Dermatology, 2006
- Parry-Romberg syndrome with fatal brain stem involvementThe Journal of Pediatrics, 2005
- Borrelia burgdorferi DNA is undetectable by polymerase chain reaction in skin lesions of morphea, scleroderma, or lichen sclerosus et atrophicus of patients from North AmericaJournal of the American Academy of Dermatology, 1995
- Absence of Borrelia burgdorferi in patients with localized scleroderma (morphea)Journal of the American Academy of Dermatology, 1995
- Bullous morphea: Clinical, pathologic, and immunopathologic evaluation of thirteen casesJournal of the American Academy of Dermatology, 1994
- Progressive facial hemiatrophy (Parry-Romberg syndrome) and borreliosisJournal of the American Academy of Dermatology, 1990
- Congenital hemihypertrophyThe Journal of Pediatrics, 1962